Guobang Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 456 million yuan, an increase of 12.60%

Guobang Pharma released its 2025 semi-annual report, with operating revenue of 3.026 billion yuan, a year-on-year increase of 4.63%; net profit attributable to the parent company was 456 million yuan, a year-on-year increase of 12.60%. The net profit excluding non-recurring gains and losses was 436 million yuan, a year-on-year increase of 10.33%. The basic earnings per share were 0.82 yuan. The company has achieved significant results in the fields of pharmaceuticals, animal health, and plant protection, with fluoroquinolone shipments exceeding 2,000 tons, and hydrochloride doxycycline approved for CEP certification, while the Qidele series of health drinks has been launched in the market